Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1.
BACKGROUND
We hypothesized that posttreatment with 15-epi-16-parafluoro-phenoxy lipoxin A4 (ATL) could attenuate lipopolysaccharide (LPS)-induced acute lung injury in mice.


METHODS
All the animals were randomly assigned to one of six groups (n = 6 per group). In the sham-vehicle group, mice were treated with 0.9% saline 60 min after they were challenged with saline. The sham-ATL group was identical to the sham-vehicle group except that ATL (0.7 mg/kg, IV) was administered, and the sham-ZnPP group was identical to the sham-vehicle group except that Zinc protoporphyrin IX (ZnPP, 25 mg/kg IV) was administered. In the LPS-vehicle group, mice were treated with vehicle 60 min after they were challenged with LPS. The LPS-ATL group was identical to the LPS-vehicle group but received ATL. The ZnPP-ATL-LPS group was identical to the LPS-ATL group, but ZnPP was administered 30 min before ATL.


RESULTS
Inhalation of LPS increased inflammatory cell counts, tumor necrosis factor-alpha, and protein concentration in bronchoalveolar lavage fluid and also induced lung histological injury and edema. Posttreatment with ATL inhibited tumor necrosis factor-alpha, nitric oxide, and malondialdehyde production, with the outcome of decreased pulmonary edema, lipid peroxidation, and the infiltration of neutrophils in lung tissues. In addition, ATL promoted the formation of heme oxygenase-1 in the lung tissues. Heme oxygenase-1 activity was also increased in the lung tissues after ATL stimulation. The beneficial effects of ATL were abolished by ZnPP.


CONCLUSIONS
This study demonstrates that posttreatment with ATL significantly reduces LPS-induced acute lung injury in mice.
Jin
Sheng-Wei
SW
Department of Anesthesiology, Second Affiliated Hospital, Wenzhou Medical College, Wenzhou, China. jinshengwei@sohu.com
Zhang
Li
L
Lian
Qin-Quan
QQ
Liu
Dong
D
Wu
Ping
P
Yao
Shang-Long
SL
Ye
Du-Yun
DY
D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D051547:Heme Oxygenase-1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D008070:Lipopolysaccharides / Q000633:toxicity*; D044045:Lipoxins / Q000494:pharmacology / Q000627:therapeutic use*; D008171:Lung Diseases / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008070:Lipopolysaccharides; D044045:Lipoxins; C040527:lipoxin A4; D051547:Heme Oxygenase-1; D001241:Aspirin